mFOLFOX6 Plus Radiation Improved pCR in Advanced Rectal Cancer
June 4, 2015
Neoadjuvant mFOLFOX6 plus radiation improved pathologic complete response in advanced rectal cancer patients compared with 5-FU/radiation or mFOLFOX6 alone.
ASCO 2015 Colorectal Cancer
Genomic Marker Predicted Anti–PD-1 Response in Colorectal Cancer
May 30, 2015
Colorectal tumors that lacked the ability to repair DNA were found to be highly responsive to checkpoint blockade with the anti–PD-1 drug pembrolizumab.
Evidence Moves OTC Prevention of mCRC Closer to Reality
May 27, 2015
Ahead of the 2015 ASCO Annual Meeting, we are discussing over-the-counter therapies for patients with metastatic colorectal cancer with Andrew T. Chan, MD, MPH.
